KR20220124390A - Cosmetic composition for preventing or improving hair loss symptoms containing black soybean, green tangerine and turmeric extract - Google Patents
Cosmetic composition for preventing or improving hair loss symptoms containing black soybean, green tangerine and turmeric extract Download PDFInfo
- Publication number
- KR20220124390A KR20220124390A KR1020210027921A KR20210027921A KR20220124390A KR 20220124390 A KR20220124390 A KR 20220124390A KR 1020210027921 A KR1020210027921 A KR 1020210027921A KR 20210027921 A KR20210027921 A KR 20210027921A KR 20220124390 A KR20220124390 A KR 20220124390A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- hair loss
- preventing
- weight
- improving hair
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 201000004384 Alopecia Diseases 0.000 title claims abstract description 25
- 208000024963 hair loss Diseases 0.000 title claims abstract description 24
- 244000068988 Glycine max Species 0.000 title claims abstract description 22
- 235000010469 Glycine max Nutrition 0.000 title claims abstract description 22
- 239000002537 cosmetic Substances 0.000 title claims description 23
- 230000003752 improving hair Effects 0.000 title claims description 12
- 208000024891 symptom Diseases 0.000 title claims description 11
- 239000008513 turmeric extract Substances 0.000 title description 9
- 229940052016 turmeric extract Drugs 0.000 title description 9
- 235000020240 turmeric extract Nutrition 0.000 title description 9
- 241000675108 Citrus tangerina Species 0.000 title 1
- 239000000284 extract Substances 0.000 claims abstract description 47
- 241001672694 Citrus reticulata Species 0.000 claims abstract description 27
- 244000163122 Curcuma domestica Species 0.000 claims abstract description 20
- 235000003373 curcuma longa Nutrition 0.000 claims abstract description 20
- 230000003676 hair loss Effects 0.000 claims abstract description 12
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims description 41
- 241001107116 Castanospermum australe Species 0.000 claims description 13
- 235000021279 black bean Nutrition 0.000 claims description 13
- 235000003392 Curcuma domestica Nutrition 0.000 claims description 10
- 235000020712 soy bean extract Nutrition 0.000 claims description 10
- 235000013976 turmeric Nutrition 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- -1 skin Substances 0.000 claims description 8
- 239000002674 ointment Substances 0.000 claims description 7
- 239000007921 spray Substances 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 5
- 229940069765 bean extract Drugs 0.000 claims description 3
- 235000012424 soybean oil Nutrition 0.000 claims description 3
- 239000003549 soybean oil Substances 0.000 claims description 3
- 238000003287 bathing Methods 0.000 claims description 2
- 239000003599 detergent Substances 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 210000002966 serum Anatomy 0.000 claims description 2
- 239000002453 shampoo Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 235000012054 meals Nutrition 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 23
- 210000004209 hair Anatomy 0.000 description 19
- 239000008213 purified water Substances 0.000 description 15
- 239000013543 active substance Substances 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 13
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 206010040880 Skin irritation Diseases 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 230000003698 anagen phase Effects 0.000 description 5
- 239000003205 fragrance Substances 0.000 description 5
- 230000003779 hair growth Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000036556 skin irritation Effects 0.000 description 5
- 231100000475 skin irritation Toxicity 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 4
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000002500 effect on skin Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 230000007794 irritation Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 101150051290 BLNK gene Proteins 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 230000003797 telogen phase Effects 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 229960000458 allantoin Drugs 0.000 description 2
- 239000002981 blocking agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- 230000003778 catagen phase Effects 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 239000003974 emollient agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 230000031774 hair cycle Effects 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 2
- 230000000774 hypoallergenic effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 231100000430 skin reaction Toxicity 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 229940099259 vaseline Drugs 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229960000271 arbutin Drugs 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 210000000442 hair follicle cell Anatomy 0.000 description 1
- 229940124563 hair growth stimulant Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000004531 microgranule Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 230000007958 sleep Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 검정콩, 풋귤 및 울금 추출물을 포함하는 탈모 증상 예방 또는 개선용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for preventing or improving hair loss symptoms comprising extracts of black beans, green tangerines and turmeric.
모발은 머리보호, 외향에 대한 영향, 머리의 온도유지 등 인체에서 다양한 역할을 담당하고 있으며, 생명유지에 중요한 기관은 아니지만, 건강상태의 척도이자 외모를 결정짓는 신체의 중요한 일부분이다.Hair is responsible for various roles in the human body, such as protecting the head, affecting the appearance, and maintaining the temperature of the head.
인체의 모발은 10만 ∼ 15만개 정도로, 각각의 모발은 서로 다른 주기를 가지며 정상모발의 90%를 차지하는 성장기(anagen, growing phase), 생장정지와 모근이 위축되는 퇴행기(catagen, transitional phase), 모구가 건조되고 곤봉모가 되는 휴지기(telogen, resting phase) 등의 모주기(hair cycle)를 거치면서 모발은 성장과 탈모를 거듭한다. 이러한 주기는 3 ∼ 6년에 걸쳐 반복되는데 그 결과 정상적으로 하루 평균 50 ∼ 100개의 모발이 탈락하게 된다.The human body has about 100,000 to 150,000 hairs, and each hair has a different cycle and accounts for 90% of normal hair in the anagen (growing phase), growth stop and catagen (transitional phase), in which the hair roots are atrophied. Hair goes through a hair cycle, such as a telogen, resting phase, in which the hair follicle dries and becomes a club hair, and hair grows and loses hair repeatedly. This cycle is repeated over 3 to 6 years, and as a result, an average of 50 to 100 hairs are normally lost per day.
탈모(alopecia)는 모발의 성장 주기에서 성장기의 모발 비율이 짧아지고 퇴행기 또는 휴지기의 모발이 많아져 비정상적으로 모발의 탈락이 증가하고, 정상적으로 자라던 모발이 어떤 원인에 의해 빠지게 되는 현상을 일컫는다. 스트레스나 질병으로 인한 탈모가 아닌 대부분의 탈모는 모발이 영양을 잃어가며 자연스럽게 굵기가 가늘어지고 약해져서 빠지게 되고, 이런 주기가 빨라지면서 모발이 재생되지 않는 탈모가 되는 것이다. 탈모는 불균형한 식생활, 과다한 음주와 흡연, 약물복용, 수면부족, 스트레스, 출산, 환경오염, 유전, 잦은 파마와 염색, 호르몬의 불균형 등에 기인하여 발생하는 것으로 알려져 있다.Alopecia refers to a phenomenon in which the proportion of hair in the growth phase is shortened in the hair growth cycle and the hair in the degenerative phase or telogen phase increases, abnormally increased hair loss, and the normally grown hair falls out due to some cause. Most hair loss, other than hair loss due to stress or disease, causes the hair to lose nutrients and naturally become thinner and weaker and fall out. Hair loss is known to occur due to unbalanced diet, excessive drinking and smoking, drug use, lack of sleep, stress, childbirth, environmental pollution, heredity, frequent perms and dyeing, and hormone imbalance.
탈모의 치료방법으로는 국소도포제, 경구복용제, 건강보조식품, 모발 이식수술 등이 있으나 이러한 방법들은 사용범위가 한정되어 있고, 지속적인 탈모완화가 이루어지지 않는다. 또한, 약물치료의 효과도 일시적이며, 두피 혹은 피지의 생성을 오히려 가속화시키기도 한다.Hair loss treatment methods include topical application agents, oral medications, health supplements, hair transplant surgery, etc. However, these methods have a limited scope of use, and continuous hair loss relief is not achieved. In addition, the effect of the drug treatment is temporary, and rather accelerates the production of the scalp or sebum.
탈모를 치료하기 위해서 성장기(Anagen)의 모낭세포를 증가시키고, 퇴행기(Catagen)와 휴지기(Telogen)의 세포를 감소시키는 방향으로 접근하고 있다. 탈모진행과정에서 감소하는 Wnt/β-catenin을 활성화시키고, 모발성장인자인 IGF-1, VEGF를 증가시킴으로써 모발 형성에 관여하는 세포를 분화시킨다.To treat hair loss, the approach is to increase hair follicle cells in the growth phase (anagen) and decrease cells in the catagen phase and telogen phase. It activates Wnt/β-catenin, which is decreased in the process of hair loss, and differentiates cells involved in hair formation by increasing IGF-1 and VEGF, which are hair growth factors.
현재 가장 많이 알려져있는 모발성장 촉진제제로서 미녹시딜(minoxidil, 경피도포제) 및 피나스테라이드(finasteride, 경구복용제) 등이 FDA 승인을 얻어 임상적으로 상용되고 있다. 특히 미녹시딜은 1970년 초에 혈관확장제로 최초로 소개되어 약물효과 이외의 부작용이 발모임이 밝혀져 현재 발모촉진제로 사용되고 있으며, 피나스테리드제제는 전립선 비대증 치료제 개발로부터 유래된 5α-reductase 억제효과를 가진 탈모 억제제로 사용되고 있다. 그러나 현재 주로 사용되는 발모제의 약물 이상반응이 보고되고 있어 적극적 치료에 상당한 제한성을 가지고 있다.Minoxidil (transdermal application) and finasteride (oral preparation), which are currently the most well-known hair growth stimulants, have been approved by the FDA and are being used clinically. In particular, minoxidil was first introduced as a vasodilator in the early 1970s, and it was found that side effects other than drug effects were hair growth, so it is currently used as a hair growth promoting agent. is being used However, there are significant limitations in active treatment as adverse drug reactions have been reported for the currently used hair growth agents.
이러한 문제점을 고려하여, 소비자가 믿고 사용할 수 있는 안전하며 탈모완화 및 발모촉진 효능이 우수한 천연 원료 개발이 필요한 실정이다.In consideration of these problems, there is a need for the development of natural raw materials that are safe for consumers to trust and use, and have excellent efficacy in alleviating hair loss and promoting hair growth.
본 발명의 목적은 탈모 예방 또는 개선용 화장료 조성물을 제공하는 것이다.It is an object of the present invention to provide a cosmetic composition for preventing or improving hair loss.
본 발명의 다른 목적은 탈모 증상 예방 또는 개선용 피부 외용제 조성물을 제공하는 것이다.Another object of the present invention is to provide a composition for external application for skin for preventing or improving hair loss symptoms.
상기 목적을 달성하기 위하여,In order to achieve the above object,
본 발명은 검정콩(Glycine max seed) 추출물, 풋귤(Citrus reticulata fruit) 추출물 및 울금(Curcuma longa root) 추출물을 포함하는 탈모 증상 예방 또는 개선용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for preventing or improving hair loss symptoms, including a black bean ( Glycine max seed) extract, a Citrus reticulata fruit extract, and a Curcuma longa root extract.
상기 검정콩은 검정콩 원물을 사용할 수도 있고, 바람직하게는 검정콩 유박(defatted Glycine max seed)을 추출 대상물로서 사용할 수 있다.The black soybean may use a black soybean raw material, preferably black soybean oil oil (defatted Glycine max seed) may be used as an extraction target.
또한, 본 발명은 검정콩(Glycine max seed) 추출물, 풋귤(Citrus reticulata fruit) 추출물 및 울금(Curcuma longa root) 추출물을 포함하는 탈모 증상 예방 또는 개선용 피부 외용제 조성물을 제공한다.In addition, the present invention provides a composition for external application for skin for preventing or improving hair loss symptoms, comprising a black bean ( Glycine max seed) extract, a green tangerine ( Citrus reticulata fruit) extract, and a turmeric ( Curcuma longa root) extract.
상기 검정콩은 검정콩 원물을 사용할 수도 있고, 바람직하게는 검정콩 유박(defatted Glycine max seed)을 추출 대상물로서 사용할 수 있다.The black soybean may use a black soybean raw material, preferably black soybean oil oil (defatted Glycine max seed) may be used as an extraction target.
본 발명에 따른 검정콩(Glycine max seed) 추출물, 풋귤(Citrus reticulata fruit) 추출물 및 울금(Curcuma longa root) 추출물을 포함하는 조성물은 탈모 예방 또는 개선 효능이 우수한 효과가 있다.A composition comprising a black bean ( Glycine max seed) extract, a Citrus reticulata fruit extract and a Curcuma longa root extract according to the present invention has an excellent effect in preventing or improving hair loss.
도 1은 검정콩 추출물의 제조 단계를 나타낸 순서도이다.
도 2는 풋귤 추출물의 제조 단계를 나타낸 순서도이다.
도 3은 울금 추출물의 제조 단계를 나타낸 순서도이다.1 is a flow chart showing the manufacturing steps of black soybean extract.
2 is a flowchart showing the steps of preparing a green tangerine extract.
Figure 3 is a flow chart showing the manufacturing steps of turmeric extract.
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
화장료 조성물cosmetic composition
본 발명은 유효물질을 포함하는 화장료 조성물을 제공한다.The present invention provides a cosmetic composition comprising an active substance.
상기 화장료 조성물은, 예를 들면 용액, 겔, 고체 또는 반죽 무수 생성물, 수상에 유상을 분산시켜 얻은 에멀젼, 현탁액, 마이크로에멀젼, 마이크로캡슐, 미세과립구 또는 이온형(리포좀), 비이온형의 소낭 분산제의 형태일 수 있다. 더욱 구체적인 형태로는 화장수, 유액, 크림, 스킨, 로션, 세럼, 에센스, 에멀젼, 파우더, 화장연고, 스프레이, 젤, 팩, 클렌저, 비누, 샴푸, 린스, 입욕제, 세정제 또는 콘실 스틱의 형태로 제공될 수 있다. 또한, 폼(foam)의 형태 또는 압축된 추진제를 더 함유한 에어로졸 조성물의 형태로도 제조될 수 있다.The cosmetic composition is, for example, a solution, a gel, a solid or kneaded anhydrous product, an emulsion obtained by dispersing an oil phase in an aqueous phase, a suspension, a microemulsion, a microcapsule, a microgranule or an ionic (liposome), a nonionic vesicle dispersant may be in the form of More specific forms include lotions, emulsions, creams, skins, lotions, serums, essences, emulsions, powders, cosmetic ointments, sprays, gels, packs, cleansers, soaps, shampoos, conditioners, bathing agents, detergents, or in the form of sticks. can be In addition, it may be prepared in the form of a foam or in the form of an aerosol composition further containing a compressed propellant.
또한, 상기 화장료 조성물은 본 발명의 유효물질에 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 화장품에 통상적으로 사용되는 임의의 다른 성분과 같은 화장품 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다.In addition, the cosmetic composition comprises a fatty substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant, Commonly used in water, ionic or nonionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic actives, lipid vesicles or cosmetics It may contain adjuvants commonly used in the cosmetic field, such as any other ingredients that are used.
본 발명의 유효물질을 함유하는 화장료 조성물에 있어서, 통상적으로 함유되는 화장료 조성물에 본 발명의 유효물질이 0.1 내지 50 중량%, 바람직하게는 1 내지 10 중량%의 양으로 첨가될 수 있다.In the cosmetic composition containing the active substance of the present invention, the active substance of the present invention may be added in an amount of 0.1 to 50% by weight, preferably 1 to 10% by weight, to the cosmetic composition usually contained.
본 발명의 유효물질을 피부 외용제로 사용하는 경우, 추가로 지방 물질, 유기 용매, 용해제, 농축제 및 겔화제, 연화제, 항산화제, 현탁화제, 안정화제, 발포제(foaming agent), 방향제, 계면활성제, 물, 이온형 또는 비이온형 유화제, 충전제, 금속이온봉쇄제 및 킬레이트화제, 보존제, 비타민, 차단제, 습윤화제, 필수 오일, 염료, 안료, 친수성 또는 친유성 활성제, 지질 소낭 또는 피부용 외용제에 통상적으로 사용되는 임의의 다른 성분과 같은 피부 과학 분야에서 통상적으로 사용되는 보조제를 함유할 수 있다. 또한, 상기 성분들은 피부 과학 분야에서 일반적으로 사용되는 양으로 도입될 수 있다.When the active substance of the present invention is used as an external preparation for skin, additionally, a fatty substance, an organic solvent, a solubilizer, a thickening agent and a gelling agent, an emollient, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, a surfactant , water, ionic or non-ionic emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid vesicles or for external use on the skin It may contain adjuvants commonly used in the field of dermatology, such as any other ingredients used as a skin care product. In addition, the above ingredients may be introduced in an amount generally used in the field of dermatology.
피부 외용제 조성물Composition for external application for skin
본 발명의 조성물에 포함되는 성분은 상기 유효성분 이외에 피부 외용제 조성물에 통상적으로 이용되는 성분들을 포함할 수 있으며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체, 부형제 및/또는 희석제를 포함할 수 있다. 제제화에 적합한 담체, 부형제 및 희석제의 예로는, 락토즈, 덱스트로즈, 수크로즈, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말디톨, 전분, 아카시아고무, 알지네이트, 젤라틴, 칼슘포스페이트, 칼슘실리케이트, 셀룰로즈, 메틸셀룰로즈, 미정질셀룰로즈, 폴리비닐피롤리돈, 물, 메틸하이드록시벤조에이트, 프로필하이드록시벤조에이트, 탈크, 마그네슘스테아레이트 또는 광물유 등이 사용될 수 있다.The ingredients included in the composition of the present invention may include ingredients commonly used in external composition for skin in addition to the active ingredient, for example, conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, and carriers, excipients and/or diluents. Examples of suitable carriers, excipients and diluents for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, malditol, starch, acacia gum, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, Methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil may be used.
의약품에 적용할 경우에는 통상 사용되는 무기 또는 유기의 담체를 가하여 고체, 반고체 또는 액상의 형태로 비경구 투여제로 제제화할 수 있다.When applied to pharmaceuticals, it can be formulated as a parenteral administration in the form of a solid, semi-solid or liquid by adding a commonly used inorganic or organic carrier.
본 발명의 유효성분을 제제화하기 위해서는 상법에 따라서 실시하면 용이하게 제제화할 수 있으며 계면활성제, 부형제, 착색료, 향신료, 보존제, 안정제, 완충제, 현탁제, 기타 상용화하는 보조제를 적당히 사용할 수 있다.In order to formulate the active ingredient of the present invention, it can be easily formulated according to a conventional method, and surfactants, excipients, colorants, spices, preservatives, stabilizers, buffers, suspending agents, and other compatibilizing adjuvants can be appropriately used.
본 발명의 피부 외용제 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 연고, 패치, 젤, 크림 또는 분무제의 형태로 제형화될 수 있으나, 이에 한정되는 것은 아니다.The composition for external application for skin of the present invention may be prepared in any formulation conventionally prepared in the art, for example, may be formulated in the form of an ointment, patch, gel, cream or spray, but is not limited thereto. .
이하, 본 발명을 하기의 실시예에 의하여 더욱 상세하게 설명한다. 단, 하기의 실시예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기의 실시예에 의해 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples only illustrate the present invention, and the content of the present invention is not limited by the following examples.
<제조예 1> 검정콩(<Preparation Example 1> Black beans ( Glycine maxGlycine max seed) 추출물의 제조 seed) preparation of extract
도 1의 제조 단계와 같이 검정콩 추출물을 제조하였다. 검정콩(Glycine max) 씨앗을 압착 착유하여 유박을 얻는다. 상기 유박 50 g에 정제수 1L 혼합 후 프로테아제로서 Protamex®(제조사: novozymes) 및 Flavourzyme®(제조사: novozymes) 각각 0.5g 혼합하여, 50℃에서 4시간 동안 효소가수분해하여 추출액을 얻었다. 상기 추출액을 filter paper (Filter paper, Hyundai Micro, 1~2 ㎛)로 여과하였다. 상기 여과한 여과액은 우선 90℃에서 5분이상 가열하여 비활성화시킨 다음 동결건조기로 건조하여 검정콩 추출물을 제조하였다.Black soybean extract was prepared as in the preparation step of FIG. 1 . Black soybean ( Glycine max ) seeds are pressed and milked to obtain oilmeal. After mixing 1L of purified water with 50 g of the oil cake, 0.5 g of each of Protamex ® (manufacturer: novozymes) and Flavorzyme ® (manufacturer: novozymes) as a protease was mixed, and enzymatically hydrolyzed at 50° C. for 4 hours to obtain an extract. The extract was filtered with filter paper (Filter paper, Hyundai Micro, 1-2 μm). The filtered filtrate was first inactivated by heating at 90° C. for 5 minutes or more, and then dried with a freeze dryer to prepare a black soybean extract.
<제조예 2> 풋귤(<Preparation Example 2> Green tangerine ( Citrus reticulataCitrus reticulata fruit) 추출물의 제조 fruit) Preparation of extract
도 2의 제조단계와 같이 풋귤 추출물을 제조하였다. 풋귤 미성숙 열매(Citrus reticulata fruit) 100 g에 추출용매로 증류수 900 mL을 넣고 shaking water bath(KMC-1205SW1, Vision, 대전, 한국)에서 90℃, 3시간 추출하여 추출액을 얻었다. 상기 추출액을 filter paper (Filter paper, Hyundai Micro, 1~2 ㎛)로 여과하였다. 상기 여과한 여과액을 동결건조기를 이용하여 건조하여 풋귤 추출물을 제조하였다.A green tangerine extract was prepared as in the preparation step of FIG. 2 . To 100 g of unripe Citrus reticulata fruit, 900 mL of distilled water was added as an extraction solvent, and extraction was performed at 90° C. for 3 hours in a shaking water bath (KMC-1205SW1, Vision, Daejeon, Korea) to obtain an extract. The extract was filtered with filter paper (Filter paper, Hyundai Micro, 1-2 μm). The filtered filtrate was dried using a freeze dryer to prepare a green tangerine extract.
<제조예 3> 울금(<Preparation Example 3> Turmeric ( Curcuma longaCurcuma longa root) 추출물의 제조 root) preparation of extract
도 3의 제조 단계와 같이 울금 추출물을 제조하였다. 울금(Curcuma longa) 뿌리 100 g에 추출용매로 증류수 900 mL을 넣고 shaking water bath(KMC-1205SW1, Vision, Daejeon, Korea)에서 90℃, 3시간 추출하여 추출액을 얻었다. 상기 추출액을 filter paper (Filter paper, Hyundai Micro, 1~2 ㎛)로 여과하였다. 상기 여과한 여과액을 동결건조기를 이용하여 건조하여 울금 추출물을 제조하였다.A turmeric extract was prepared as in the preparation step of FIG. 3 . To 100 g of turmeric ( Curcuma longa ) roots, 900 mL of distilled water was added as an extraction solvent, and extraction was performed at 90° C. for 3 hours in a shaking water bath (KMC-1205SW1, Vision, Daejeon, Korea) to obtain an extract. The extract was filtered with filter paper (Filter paper, Hyundai Micro, 1-2 μm). The filtered filtrate was dried using a freeze dryer to prepare a turmeric extract.
<실시예 1> 검정콩(<Example 1> Black beans ( Glycine maxGlycine max seed) 추출물, 풋귤( seed) extract, green tangerine ( Citrus reticulataCitrus reticulata fruit) 추출물 및 울금( fruit) extract and turmeric ( Curcuma longaCurcuma longa root) 추출물 혼합물의 제조 root) preparation of extract mixture
제조예 1 내지 3에서 제조한 3종 추출물과 부틸렌글라이콜 및 정제수를 혼합하여 혼합물 시료를 준비하였다.A mixture sample was prepared by mixing the three extracts prepared in Preparation Examples 1 to 3, butylene glycol, and purified water.
구체적으로, 검정콩 추출물 0.1 중량%, 풋귤 추출물 0.1 중량%, 울금 추출물 0.1 중량%, 부틸렌글라이콜 40 중량% 및 정제수 잔량을 혼합하여 시료를 준비하였다.Specifically, a sample was prepared by mixing 0.1% by weight of black bean extract, 0.1% by weight of green tangerine extract, 0.1% by weight of turmeric extract, 40% by weight of butylene glycol and the remaining amount of purified water.
<비교예 1> 검정콩 추출물 시료의 제조<Comparative Example 1> Preparation of black soybean extract sample
제조예 1에서 제조한 검정콩 추출물 0.3 중량%, 부틸렌글라이콜 40 중량% 및 정제수 잔량을 혼합하여 시료를 준비하였다.A sample was prepared by mixing 0.3% by weight of the black soybean extract prepared in Preparation Example 1, 40% by weight of butylene glycol, and the remaining amount of purified water.
<비교예 2> 풋귤 추출물 시료의 제조<Comparative Example 2> Preparation of green tangerine extract sample
제조예 2에서 제조한 풋귤 추출물 0.3 중량%, 부틸렌글라이콜 40 중량% 및 정제수 잔량을 혼합하여 시료를 준비하였다.A sample was prepared by mixing 0.3% by weight of the green tangerine extract prepared in Preparation Example 2, 40% by weight of butylene glycol, and the remaining amount of purified water.
<비교예 3> 울금 추출물 시료의 제조<Comparative Example 3> Preparation of turmeric extract sample
제조예 3에서 제조한 울금 추출물 0.3 중량%, 부틸렌글라이콜 40 중량% 및 정제수 잔량을 혼합하여 시료를 준비하였다.A sample was prepared by mixing 0.3% by weight of the turmeric extract prepared in Preparation Example 3, 40% by weight of butylene glycol, and the remaining amount of purified water.
<비교예 4> 검정콩 추출물 및 풋귤 추출물 포함 시료의 제조<Comparative Example 4> Preparation of samples containing black soybean extract and green tangerine extract
제조예 1에서 제조한 검정콩 추출물 0.15 중량%, 제조예 2에서 제조한 풋귤 추출물 0.15 중량% 및 부틸렌글라이콜 40 중량% 및 정제수 잔량을 혼합하여 시료를 준비하였다.A sample was prepared by mixing 0.15% by weight of the black soybean extract prepared in Preparation Example 1, 0.15% by weight of the green tangerine extract prepared in Preparation Example 2, 40% by weight of butylene glycol, and the remaining amount of purified water.
<비교예 5> 검정콩 추출물 및 울금 추출물 포함 시료의 제조<Comparative Example 5> Preparation of samples containing black soybean extract and turmeric extract
제조예 1에서 제조한 검정콩 추출물 0.15 중량%, 제조예 3에서 제조한 울금 추출물 0.15 중량%, 부틸렌글라이콜 40 중량% 및 정제수 잔량을 혼합하여 시료를 준비하였다.A sample was prepared by mixing 0.15% by weight of the black bean extract prepared in Preparation Example 1, 0.15% by weight of the turmeric extract prepared in Preparation Example 3, 40% by weight of butylene glycol, and the remaining amount of purified water.
<실험예 1> 인간모유두세포 세포생존율 평가<Experimental Example 1> Human hair papilla cell cell viability evaluation
실시예 및 비교예에서 준비한 시료를 인간모유두세포에 처리하여 세포생존율을 평가하여, 탈모 효능을 알아보았다.The samples prepared in Examples and Comparative Examples were treated with human hair papilla cells to evaluate cell viability, and hair loss efficacy was investigated.
WST(high sensitivity water soluble tetrazolium salts)는 세포 내의 디하이드로게나제(dehydrogenase)와 반응하여 포르마잔(formazan)을 생성한다. 따라서 살아있는 세포가 많을수록 포르마잔의 생성이 많아 높은 흡광도를 나타내며, 이를 이용하여 세포의 독성 정도를 판단할 수 있다.High sensitivity water soluble tetrazolium salts (WST) react with dehydrogenase in the cell to generate formazan. Therefore, the more live cells there are, the more formazan is produced, which indicates a high absorbance, which can be used to determine the degree of toxicity of the cells.
본 시험에 사용한 인간모유두세포(Human Follicle Dermal Papilla Cell; 제조사: Promo cell)는 Human Follicle Dermal Papilla Cell Growth Medium (제조사: PromoCell)에 Fetal Calf Serum, Bovine Pituitary Extract, Basic Fibroblast Growth Factor, Insulin을 첨가한 배지에서 37℃, 5% CO2 조건으로 배양시켰다.Human Follicle Dermal Papilla Cell (Manufacturer: Promo cell) used in this test was prepared by adding Fetal Calf Serum, Bovine Pituitary Extract, Basic Fibroblast Growth Factor, and Insulin to Human Follicle Dermal Papilla Cell Growth Medium (Manufacturer: PromoCell). It was cultured in a medium at 37° C., 5% CO 2 condition.
배양된 세포는 96-웰 플레이트에 5 X 103개로 나누어 분주하여 80% 이상 배양되었을 때 시료를 5가지 농도로 처리한 후 24, 48시간 동안 배양하였다. 이후 배지에 WST 기질 용액(모델명: CCK-8; 제조사: Dojindo)을 넣고 37℃에서 2시간 동안 배양하였다.The cultured cells were divided into 5 X 10 3 pieces in a 96-well plate, and when cultured to 80% or more, the samples were treated at 5 concentrations and then cultured for 24 or 48 hours. Then, a WST substrate solution (Model: CCK-8; Manufacturer: Dojindo) was added to the medium and incubated at 37°C for 2 hours.
Microplate reader (VARIOSKAN LUX, Thermo Fisher Scientific)를 이용하여 450nm에서 흡광도(OD)를 측정하고, 아래의 식에 의해 계산하여 세포 생존율을 계산하였다.The absorbance (OD) was measured at 450 nm using a microplate reader (VARIOSKAN LUX, Thermo Fisher Scientific), and the cell viability was calculated by the following equation.
세포생존율(%)= (ODexp-ODblnk)/(ODcon-ODblnk) X 100Cell viability (%) = (OD exp -OD blnk )/(OD con -OD blnk ) X 100
- blank(blnk): WST 기질을 포함하는 배지- blank (blnk): medium containing WST substrate
- Control(con, 음성대조군): 시료 비처리군- Control (con, negative control): untreated group
- Experiment(exp, 실험군): 시료 처리군- Experiment(exp, experimental group): sample treatment group
상기 표 1에 나타난 바와 같이, 비교예 1 내지 5 대비 실시예 1의 3종 추출물 콤플렉스 시료의 경우 인간모유두세포 생존율이 현저히 향상됨을 확인할 수 있었다. 특히, 25 ppm 처리농도에서 시료처리 배양 24시간 후 대비 48시간 후에 비교예 1 내지 5는 모두 세포 생존율이 감소하는 것으로 나타난 반면에, 실시예 1의 경우 24시간 후 대비 48시간 후에 세포 생존율이 더욱 향상되는 것으로 나타났다.As shown in Table 1, in the case of the three extract complex samples of Example 1 compared to Comparative Examples 1 to 5, it was confirmed that the survival rate of human hair papilla cells was significantly improved. In particular, Comparative Examples 1 to 5 all showed a decrease in cell viability after 48 hours compared to 24 hours after sample treatment at a treatment concentration of 25 ppm, whereas in Example 1, cell viability was higher after 24 hours compared to after 48 hours. appeared to improve.
<실험예 2> 피부 자극성 평가<Experimental Example 2> Skin irritation evaluation
실시예 1 시료의 피부 자극성을 평가하여 안전성을 알아보았다.Example 1 The safety of the sample was evaluated by evaluating the skin irritation.
실시예 1의 시료를 1% 희석액 상태로 준비하여, 성인 31명을 대상으로 하여 24시간 첩포 시험을 실시하였다. 패치 제거 후 30분, 24시간, 48시간에 각각 일차 피부자극 유무를 피부과 전문의가 판정하였다. The sample of Example 1 was prepared in a 1% dilution state, and a 24-hour patch test was performed on 31 adults. A dermatologist judged the presence or absence of primary skin irritation at 30 minutes, 24 hours, and 48 hours after patch removal, respectively.
피부 자극성 점수 시스템은 하기와 같이 하였다.The skin irritation scoring system was as follows.
<피부 자극성 점수 시스템 표><Skin irritation score system table>
연구 대상자들의 피부 반응 점수를 이용하여 다음과 같이 자극지수를 계산하였다.The irritation index was calculated as follows using the skin response scores of the study subjects.
평균 자극 지수를 산출한 후 Draize Dermal Classification System 및 EPA (Environmental Protection Agency) Standard Procedure Dermal Classification System을 응용한 다음 결과 판정표에 따라 자극성의 정도를 판정한다.After calculating the average irritation index, the Draize Dermal Classification System and EPA (Environmental Protection Agency) Standard Procedure Dermal Classification System are applied, and then the degree of irritation is determined according to the result judgment table.
피부반응 판정은 ICDRG(International contact dermatitis research group) 기준 및 PCPC(Personal Care Products Council) 가이드라인에 의거하였으며, 31명 연구대상자들의 피부반응 점수를 이용하여 자극 지수를 산출한 결과 피부자극 지수 0.027점을 얻어, 저자극 시료임을 확인하였다.Skin reaction determination was based on ICDRG (International contact dermatitis research group) standards and PCPC (Personal Care Products Council) guidelines. obtained, and it was confirmed that it was a hypoallergenic sample.
화장료의 제조예Preparation example of cosmetics
본 발명에 따른 유효물질은 목적에 따라 여러 형태의 화장료로 제조 가능하다. 하기는 본 발명에 따른 유효물질을 활성성분으로 함유시킨 몇몇 화장료의 제조방법을 예시한 것으로 본 발명이 이에 한정되는 것은 아니다.The active substance according to the present invention can be prepared into various types of cosmetics depending on the purpose. The following exemplifies the manufacturing method of several cosmetics containing the active ingredient according to the present invention as an active ingredient, but the present invention is not limited thereto.
<화장료 제조예 1> 유연 화장수의 제조<Cosmeceutical preparation example 1> Preparation of softened lotion
유효물질 10.0 중량부active substance 10.0 parts by weight
1,3-부틸렌글리콜 1.00 중량부1,3-butylene glycol 1.00 parts by weight
디소듐이디티에이 0.05 중량부Disodium EDIT 0.05 parts by weight
알란토인 0.10 중량부allantoin 0.10 parts by weight
디포타슘글리시리제이트 0.05 중량부Dipotassium glycyrrhizate 0.05 parts by weight
시트르산 0.01 중량부citric acid 0.01 parts by weight
소듐시트레이트 0.02 중량부sodium citrate 0.02 parts by weight
글리세레스-26 1.00 중량부Glyceres-26 1.00 parts by weight
알부틴 2.00 중량부arbutin 2.00 parts by weight
하이드로제네이티드캐스터오일 1.00 중량부Hydrogenated Castor Oil 1.00 parts by weight
에탄올 30.0 중량부ethanol 30.0 parts by weight
보존제 미량preservative a very small amount
착색제 미량coloring agent a very small amount
착향제 미량flavoring agent a very small amount
정제수 잔량Purified water remaining amount
<화장료 제조예 2> 영양 크림의 제조<Cosmeceutical Preparation Example 2> Preparation of nourishing cream
유효물질 10.0 중량부active substance 10.0 parts by weight
1,3-부틸렌글리콜 7.00 중량부1,3-butylene glycol 7.00 parts by weight
글리세린 1.00 중량부glycerin 1.00 parts by weight
D-판테놀 0.10 중량부D-Panthenol 0.10 parts by weight
식물 추출물 3.20 중량부plant extract 3.20 parts by weight
마그네슘알루미늄실리케이트 0.30 중량부Magnesium Aluminum Silicate 0.30 parts by weight
PEG-40 스테아레이트 1.20 중량부PEG-40 Stearate 1.20 parts by weight
스테아르산 2.00 중량부stearic acid 2.00 parts by weight
폴리소르베이트 60 1.50 중량부Polysorbate 60 1.50 parts by weight
친유형글리세릴스테아레이트 2.00 중량부Lipophilic Glyceryl Stearate 2.00 parts by weight
소르비탄세스퀴올리에이트 1.50 중량부Sorbitan sesquioleate 1.50 parts by weight
세테아릴알코올 3.00 중량부cetearyl alcohol 3.00 parts by weight
미네랄오일 4.00 중량부mineral oil 4.00 parts by weight
스쿠알란 3.80 중량부squalane 3.80 parts by weight
카르릴릭/카프릭트리글리세라이드 2.80 중량부Carlylic/Capric Triglycerides 2.80 parts by weight
식물성오일 1.80 중량부vegetable oil 1.80 parts by weight
디메치콘 0.40 중량부dimethicone 0.40 parts by weight
디포슘글리시리제이트 미량Dipotassium glycyrrhizate a very small amount
알란토인 미량allantoin a very small amount
소듐 히아루로네이트 미량Sodium Hyaluronate a very small amount
토코페릴아세테이트 적량Tocopheryl Acetate appropriate amount
트리에탄올아민 적량triethanolamine appropriate amount
보존제 적량preservative appropriate amount
착향제 적량flavoring agent appropriate amount
정제수 잔량Purified water remaining amount
피부 외용제의 제조예Preparation example of external preparation for skin
본 발명에 따른 유효물질은 목적에 따라 여러 형태로 제제화가 가능하다. 하기는 본 발명에 따른 유효물질을 활성성분으로 함유시킨 몇몇 제제화 방법을 예시한 것으로 본 발명이 이에 한정되는 것은 아니다.The active substance according to the present invention can be formulated in various forms depending on the purpose. The following exemplifies some formulation methods containing the active substance according to the present invention as an active ingredient, but the present invention is not limited thereto.
<피부 외용제 제조예 1> 분무제의 제조<Skin external preparation Preparation Example 1> Preparation of spray
유효물질 100 mgactive substance 100 mg
이성화당 10 gLee Seonghwadang 10 g
만니톨 5 gmannitol 5 g
정제수 적량Purified water appropriate amount
통상의 분무제의 제조방법에 따라, 정제수에 각각의 성분을 가하여 용해시키고 레몬 향을 가한 다음 상기의 성분을 혼합한 다음 정제수를 가하여 전체 100 mL로 조절한 후 갈색 병에 충진하고 멸균시켜 분무제를 제조하였다.According to a conventional method for producing a spray, add each component to purified water to dissolve, add lemon flavor, mix the above ingredients, add purified water to adjust the total to 100 mL, fill in a brown bottle, and sterilize to prepare a spray did.
<피부 외용제 제조예 2> 젤제의 제조<Production Example 2 for external application for skin> Preparation of gel
유효물질 100 mgactive substance 100 mg
에탄올 10 gethanol 10 g
글리세린 4 gglycerin 4 g
프로필렌글리콜 4 gpropylene glycol 4 g
폴리옥시에틸렌 경화피마자유 0.1 gPolyoxyethylene hydrogenated castor oil 0.1 g
카르복시폴리머 0.3 gcarboxy polymer 0.3 g
트리에탄올아민 0.3gtriethanolamine 0.3g
산화방지제 적량antioxidant appropriate amount
향료 적량Spices appropriate amount
방부제 적량antiseptic appropriate amount
정제수 적량Purified water appropriate amount
통상의 젤제의 제조방법에 따라, 정제수에 각각의 성분을 가하여 용해시키고 향료를 가한 다음 상기의 성분들을 혼합하여 젤제를 제조하였다.According to a conventional gel preparation method, each component was added and dissolved in purified water, a fragrance was added, and then the above components were mixed to prepare a gel.
<피부 외용제 제조예 3> 연고제의 제조<Skin external preparation Preparation Example 3> Preparation of ointment
유효물질 100 mgactive substance 100 mg
세토스테아릴알코올 2 gcetostearyl alcohol 2 g
자가유화형 모노스테아린산 2 gSelf-emulsifying monostearic acid 2 g
스테아린산 1 gstearic acid 1 g
밀납 4 gbeeswax 4 g
스쿠알란 7 gsqualane 7 g
모노스테아린 글리세린 3 gmonostearin glycerin 3 g
모노스테아린산 소르비탄 1 gMonostearate Sorbitan 1 g
폴리솔베이트 80 3 gPolysorbate 80 3 g
글리세린 5 gglycerin 5 g
프로필렌글리콜 4 gpropylene glycol 4 g
향료 적량Spices appropriate amount
바세린 잔량Vaseline remaining amount
통상의 연고제의 제조방법에 따라, 바세린에 각각의 성분을 가하여 용해시키고 향료를 가한 다음 상기의 성분들을 혼합하여 연고제를 제조하였다.According to a conventional method for preparing an ointment, each component was added to and dissolved in vaseline, a fragrance was added, and then the above components were mixed to prepare an ointment.
이제까지 본 발명에 대하여 그 바람직한 실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특히 청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.So far, with respect to the present invention, the preferred embodiments have been looked at. Those of ordinary skill in the art to which the present invention pertains will understand that the present invention may be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments are to be considered in an illustrative rather than a restrictive sense. The scope of the present invention is indicated not in the foregoing description, but in particular in the claims, and all differences within the scope equivalent thereto should be construed as being included in the present invention.
Claims (6)
Black bean ( Glycine max seed) extract, green tangerine ( Citrus reticulata fruit) extract and turmeric ( Curcuma longa root) extract, comprising a, hair loss symptom prevention or improvement cosmetic composition.
상기 검정콩 추출물은 검정콩 유박(defatted Glycine max seed) 추출물인 것을 특징으로 하는, 탈모 증상 예방 또는 개선용 화장료 조성물.
The method of claim 1,
The black soybean extract is a cosmetic composition for preventing or improving hair loss symptoms, characterized in that the black bean extract is an extract of defatted Glycine max seed.
상기 화장료는 화장수, 유액, 크림, 스킨, 로션, 세럼, 에센스, 에멀젼, 파우더, 화장연고, 스프레이, 젤, 팩, 클렌저, 비누, 샴푸, 린스, 입욕제, 세정제 또는 콘실 스틱의 형태인 것을 특징으로 하는, 탈모 증상 예방 또는 개선용 화장료 조성물.
The method of claim 1,
The cosmetic is in the form of a lotion, emulsion, cream, skin, lotion, serum, essence, emulsion, powder, cosmetic ointment, spray, gel, pack, cleanser, soap, shampoo, conditioner, bathing agent, detergent or cone stick. A cosmetic composition for preventing or improving hair loss symptoms.
Black bean ( Glycine max seed ) extract, green tangerine ( Citrus reticulata fruit ) extract and turmeric ( Curcuma longa root ) extract, comprising a skin external composition for preventing or improving hair loss symptoms.
상기 검정콩 추출물은 검정콩 유박(defatted Glycine max seed) 추출물인 것을 특징으로 하는, 탈모 증상 예방 또는 개선용 피부 외용제 조성물.
5. The method of claim 4,
The black soybean extract is a skin external composition for preventing or improving hair loss symptoms, characterized in that the black soybean oil meal (defatted Glycine max seed) extract.
상기 피부 외용제는 연고, 패치, 젤, 크림 또는 분무제의 형태인 것을 특징으로 하는, 탈모 증상 예방 또는 개선용 피부 외용제 조성물.5. The method of claim 4,
The external preparation for skin is an ointment, patch, gel, cream or spray, characterized in that the skin external application composition for preventing or improving hair loss symptoms.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210027921A KR102602321B1 (en) | 2021-03-03 | 2021-03-03 | Cosmetic composition for preventing or improving hair loss symptoms containing black soybean, green tangerine and turmeric extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020210027921A KR102602321B1 (en) | 2021-03-03 | 2021-03-03 | Cosmetic composition for preventing or improving hair loss symptoms containing black soybean, green tangerine and turmeric extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20220124390A true KR20220124390A (en) | 2022-09-14 |
KR102602321B1 KR102602321B1 (en) | 2023-11-14 |
Family
ID=83278984
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020210027921A KR102602321B1 (en) | 2021-03-03 | 2021-03-03 | Cosmetic composition for preventing or improving hair loss symptoms containing black soybean, green tangerine and turmeric extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102602321B1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030083159A (en) * | 2002-04-19 | 2003-10-30 | 주식회사 엘지생활건강 | Composition for preventing and treating of androgen-dependent disorders comprising curcuma longa extract |
KR20100010647A (en) * | 2008-07-23 | 2010-02-02 | (주)아모레퍼시픽 | Patch for inhibiting hair loss and enhancing hair growth |
KR20110104196A (en) * | 2010-03-16 | 2011-09-22 | (주)아모레퍼시픽 | Composition for prevention of losing hair or promotion of growing hair |
KR20130122070A (en) * | 2012-04-30 | 2013-11-07 | (주)아모레퍼시픽 | Hair cosmetic composition containing extract of camellia japonica l. seed |
KR101424175B1 (en) | 2012-12-26 | 2014-08-01 | 대구가톨릭대학교산학협력단 | Method for producing composition for preventing hair loss or stimulating hair growth with increased antioxidant ability and hair growth ability comprising extracts of black bean, hasuo, gamtae and sea tangle |
-
2021
- 2021-03-03 KR KR1020210027921A patent/KR102602321B1/en active IP Right Grant
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030083159A (en) * | 2002-04-19 | 2003-10-30 | 주식회사 엘지생활건강 | Composition for preventing and treating of androgen-dependent disorders comprising curcuma longa extract |
KR20100010647A (en) * | 2008-07-23 | 2010-02-02 | (주)아모레퍼시픽 | Patch for inhibiting hair loss and enhancing hair growth |
KR20110104196A (en) * | 2010-03-16 | 2011-09-22 | (주)아모레퍼시픽 | Composition for prevention of losing hair or promotion of growing hair |
KR20130122070A (en) * | 2012-04-30 | 2013-11-07 | (주)아모레퍼시픽 | Hair cosmetic composition containing extract of camellia japonica l. seed |
KR101424175B1 (en) | 2012-12-26 | 2014-08-01 | 대구가톨릭대학교산학협력단 | Method for producing composition for preventing hair loss or stimulating hair growth with increased antioxidant ability and hair growth ability comprising extracts of black bean, hasuo, gamtae and sea tangle |
Also Published As
Publication number | Publication date |
---|---|
KR102602321B1 (en) | 2023-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2520057A1 (en) | Composition for promoting production of type i collagen and/or elastin | |
KR102113193B1 (en) | Composition for improving skin conditions comprising artemisiae annuae herba, centella asiatica and green tea extract or fraction thereof and method for improving skin conditions using the same | |
KR20140115400A (en) | Composition of scalp care for prevention of depilation and improvement of hair growth comprising Rhus javanica L. Extracts | |
JP3407935B2 (en) | External preparation for skin | |
KR102099087B1 (en) | Composition for Preventing Hair Loss or Improving Hair Growth | |
JP4796734B2 (en) | Matrix metalloprotease activity inhibitor | |
KR102445830B1 (en) | Cosmetic Compositions for Skin Moisture Comprising Extract of Triticum aestivum | |
JP2002370922A (en) | Cosmetic containing japanese plum extract | |
KR101820531B1 (en) | Composition for preventing hair loss or promoting hair growth with Nipa fruticans wurmb | |
KR101870377B1 (en) | Cosmetic composition for improving moisturizing and antioxidant containing ultrasonicating extract of cucumber seed | |
KR20010018805A (en) | Cosmetic compositions for anti-inflammation and anti-irritation containing ponciri fructus extracts as effective ingredients | |
US10806693B2 (en) | Method for increasing lipolysis using a composition comprising bioactive Nelumbo nucifera (lotus) extract | |
KR101762314B1 (en) | Cosmetic composition containing plant extract for improving skin condition | |
JP4247091B2 (en) | Skin anti-aging agent | |
JPH11246337A (en) | Antiaging agent | |
KR102602321B1 (en) | Cosmetic composition for preventing or improving hair loss symptoms containing black soybean, green tangerine and turmeric extract | |
JP2001081038A (en) | Scavenger for active oxygen, and cosmetic and food containing the same scavenger | |
JPH10182414A (en) | Antiaging agent | |
JP2004149729A (en) | Antioxidant | |
JPH11246387A (en) | Antiaging agent | |
JP2003342179A (en) | Agent for aging prevention | |
KR20210131598A (en) | Composition for preventing hair loss or promoting hair growth, comprising Camellia japonica pericarp extract as an active ingredient | |
KR20230141034A (en) | Cosmetic composition for preventing or improving hair loss comprising liposomes containing a mixture of black soybean, green mandarin and turmeric extract | |
KR20160061601A (en) | Cosmetic composition and pharmaceutical composition containing the extract of Corchorus olitorius L, ginko and chlorella | |
JPH11335230A (en) | Skin lotion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |